Concurrence of UGT1A Polymorphism and End-Stage Renal Disease Leads to Severe Toxicities of Irinotecan in a Patient with Metastatic Colon Cancer
Authors:
- 1 March 2011
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 97 (2) , 243-247
Abstract
Aims and background: Colorectal cancer is one of the most common malignancies in the world, and irinotecan (CPT-11) is useful in its treatment. However, the safety and pharmacokinetics of irinotecan in dialysis patients with metastatic colorectal cancer are unclear. Case report: We report the case of a 74-year-old man receiving chronic hemodialysis who had metastatic colorectal cancer. Palliative chemotherapy with irinotecan (80 mg/m2 weekly) was administered after hemodialysis. Blood samples were collected before and 1.5, 3, 6, 9, and 15 hours after administration of irinotecan. The peak serum concentrations (Cmax) of irinotecan and SN-38 in this patient were 1, 480 and 17.8 ng/mL, respectively, which were similar to the reported values in patients with normal renal function after a similar dose of irinotecan (75 mg/m2). The area under the serum concentration-time curve (AUC0-∞) was 8, 240 ng×h/mL for irinotecan and 619 ng×h/mL for SN-38. The AUC0-∞ for SN-38 was markedly higher than that for patients with normal renal function. Sequencing analysis of the UGT1A genes found that the patient had variant alleles of UGT1A1*28, UGT1A1*60 and UGT1A9*22, which may lead to decreased glucuronidation and excretion of SN-38, and may account for increased irinotecan-related toxicity. The patient developed febrile grade 4 neutropenia on day 7 after chemotherapy and died of septic shock on day 14. Conclusions: UGT1A polymorphisms and renal failure may lead to accumulation of SN-38, which may have played a role in the death of this patient. Irinotecan should be used cautiously in dialysis patients with metastatic colorectal cancer and screening for UGT1A polymorphisms may help in identifying patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan-induced toxicity.Keywords
This publication has 18 references indexed in Scilit:
- Systemic Treatment of Colorectal CancerGastroenterology, 2008
- Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A IsoformsPLOS ONE, 2007
- The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2006
- Good Tolerance of Weekly Irinotecan in a Patient with Metastatic Colorectal Cancer on Chronic HemodialysisJournal of Chemotherapy, 2005
- UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer*1Clinical Pharmacology & Therapeutics, 2004
- A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activityPharmacogenetics, 2004
- Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography–electrospray mass spectrometryJournal of Chromatography B: Biomedical Sciences and Applications, 1999
- Differential Expression of the UGT1A Locus in Human Liver, Biliary, and Gastric Tissue: Identification ofUGT1A7 and UGT1A10 Transcripts in Extrahepatic TissueMolecular Pharmacology, 1997
- Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver CarboxylesteraseBiochemical Pharmacology, 1996
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI: Journal of the National Cancer Institute, 1994